Molecular targeted therapy for glioma stem cells

doi:10.3760/cma.j.issn.1673422X.2016.12.013

Abstract

Abstract: Glioma stem cells (GSCs) are considered to be the root of migration, recurrence, and resistance to chemoradiotherapy in malignant glioma. With molecular targeting drugs becoming widespread in treating other cancers, the ones targeting GSCs could also be successful in the future. At present, relevant studies mainly concentrate in the hedgehog and PI3K pathways, and main representative drugs are cyclopamine and its derivatives, rapamycin and its derivatives, and some classical drugs like arsenic trioxide and metformin also performing the outcome of antiGSCs.

Key words: Glioma, Stem cells, Molecular targeted therapy

TONG Lu-Qing, TANG Tian-Jiao, YANG Xue-Jun. Molecular targeted therapy for glioma stem cells[J]. Journal of International Oncology, 2016, 43(12): 930-934.

References

［1］ Stopschinski BE, Beier CP, Beier D. Glioblastoma cancer stem cellsfrom concept to clinical application［J］. Cancer Lett, 2013, 338(1, SI): 3240. DOI: 10.1016/j.canlet.2012.05.033. ［2］ Balbous A, Renoux B, Cortes U, et al. Selective release of a cyclopamine glucuronide prodrug toward stemlike cancer cell inhibition in glioblastoma［J］. Mol Cancer Ther, 2014, 13(9): 21592169. DOI: 10.1158/15357163.MCT131038. ［3］ Fu J, Rodova M, Nanta R, et al. NPVLDE225 (erismodegib) inhibits epithelial mesenchymal transition and selfrenewal of glioblastoma initiating cells by regulating miR21, miR128, and miR200［J］. Neuro Oncol, 2013, 15(6): 691706. DOI: 10.1093/neuonc/not011. ［4］ Filbin MG, Dabral SK, PazyraMurphy MF, et al. Coordinate activation of Shh and PI3K signaling in PTENdeficient glioblastoma: new therapeutic opportunities［J］. Nat Med, 2013, 19(11): 1518. DOI: 10.1038/nm.3328. ［5］ Rodon J, Tawbi HA, Thomas AL, et al. A phase Ⅰ, multicenter, openlabel, firstinhuman, doseescalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors［J］. Clin Cancer Res, 2014, 20(7): 19001909. DOI: 10.1158/10780432.CCR131710. ［6］ Dixit D, Ghildiyal R, Anto NP, et al. Guggulsterone sensitizes glioblastoma cells to Sonic hedgehog inhibitor SANT1 induced apoptosis in a Ras/NFκB dependent manner［J］. Cancer Lett, 2013, 336(2): 347358. DOI: 10.1016/j.canlet.2013.03.025. ［7］ Beauchamp EM, Ringer L, Bulut G, et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway［J］. J Clin Invest, 2011, 121(1): 148160. DOI: 10.1172/JCI42874. ［8］ Zhou WC, Cheng L, Shi Y, et al. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth［J］. Oncotarget, 2015, 6(35): 3730037315. DOI: 10.18632/oncotarget.5836. ［9］ Wen PY, Omuro A, Ahluwalia MS, et al. Phase Ⅰ doseescalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with highgrade glioma［J］. Neuro Oncol, 2015, 17(9): 12751283. DOI: 10.1093/neuonc/nov083. ［10］ BagciOnder T, Wakimoto H, Anderegg MA, et al. A dual PI3K/mTOR inhibitor, PI103, cooperates with stem celldelivered TRAIL in experimental glioma models［J］. Cancer Res, 2011, 71(1): 154163. DOI: 10.1158/00085472.CAN101601. ［11］ Sato A, Sunayama J, Okada M, et al. GliomaInitiating cell elimination by metformin activation of FOXO3 via AMPK［J］. Stem Cells Transl Med, 2012, 1(11): 811824. DOI: 10.5966/sctm.20120058. ［12］ Yu Z, Zhao G, Li P, et al. Temozolomide in combination with metformin act synergistically to inhibit proliferation and expansion of glioma stemlike cells［J］. Oncol Lett, 2016, 11(4): 27922800. DOI: 10.3892/ol.2016.4315. ［13］ Zhuang WZ, Li BZ, Long LM, et al. Induction of autophagy promotes differentiation of gliomainitiating cells and their radiosensitivity［J］. Int J Cancer, 2011, 129(11): 27202731. DOI: 10.1002/ijc.25975. ［14］ GarrosRegulez L, Aldaz P, Arrizabalaga O, et al. mTOR inhibition decreases SOX2SOX9 mediated glioma stem cell activity and temozolomide resistance［J］. Expert Opin Ther Targets, 2016, 20(4): 393405. DOI: 10.1517/14728222.2016.1151002. ［15］ Ma DJ, Galanis E, Anderson SK, et al. A phase Ⅱ trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K［J］. Neuro Oncol, 2015, 17(9): 12611269. DOI: 10.1093/neuonc/nou328. ［16］ Franz DN, Agricola K, Mays M, et al. Everolimus for subependymal giant cell astrocytoma: 5year final analysis［J］. Ann Neurol, 2015, 78(6): 929938. DOI: 10.1002/ana.24523. ［17］ Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST1): a multicentre, randomised, placebocontrolled phase 3 trial［J］. Lancet, 2013, 381(9861): 125132. DOI: 10.1016/S01406736(12)611349. ［18］ Wen PY, Chang SM, Lamborn KR, et al. Phase Ⅰ/Ⅱ study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 0402［J］. Neuro Oncol, 2014, 16(4): 567578. DOI: 10.1093/neuonc/not247. ［19］ Kahn J, Hayman TJ, Jamal M, et al. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stemlike cells［J］. Neuro Oncol, 2014, 16(1): 2937. DOI: 10.1093/neuonc/not139. ［20］ Hu YY, Zheng MH, Cheng G, et al. Notch signaling contributes to the maintenance of both normal neural stem cells and patientderived glioma stem cells［J］. BMC Cancer, 2011, 11: 82. DOI: 10.1186/147124071182. ［21］ Yahyanejad S, King H, Iglesias VS, et al. NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma［J］. Oncotarget, 2016, In press. DOI: 10.18632/oncotarget.9275. ［22］ Xu R, Shimizu F, Hovinga K, et al. Molecular and clinical effects of notch inhibition in glioma patients: a phase 0/Ⅰ trial［J］. Clin Cancer Res, 2016, In press. DOI: 10.1158/10780432.CCR160048. ［23］ Krop I, Demuth T, Guthrie T, et al. Phase Ⅰ pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK0752 in adult patients with advanced solid tumors［J］. J Clin Oncol, 2012, 30(19): 23072313. DOI: 10.1200/JCO.2011.39.1540. ［24］ Wickstrm M, Dyberg C, Milosevic J, et al. Wnt/betacatenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance［J］. Nat Commun, 2015, 6: 8904. DOI: 10.1038/ncomms9904. ［25］ KierulfVieira KS, Sandberg CJ, Grieg Z, et al. Wnt inhibition is dysregulated in gliomas and its reestablishment inhibits proliferation and tumor sphere formation［J］. Exp Cell Res, 2016, 340(1): 5361. DOI: 10.1016/j.yexcr.2015.12.010.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[3]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[4]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[5]	Huang Hui, Ding Jianghua. Advances in targeting FGFR2 for treatment of advanced cholangiocarcinoma [J]. Journal of International Oncology, 2023, 50(9): 569-573.
[6]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[7]	Liu Li, Zhu Siqi, Sun Mengying, He Jingdong. Progress of PARP inhibitors in targeted therapy of small cell lung cancer [J]. Journal of International Oncology, 2023, 50(6): 368-372.
[8]	Liu Bohan, Huang Junxing. Research progress of solute carriers related genes in malignant tumors [J]. Journal of International Oncology, 2023, 50(5): 280-284.
[9]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2 [J]. Journal of International Oncology, 2023, 50(4): 236-240.
[10]	Deng Lili, Duan Xingyu, Li Baozhong. Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma [J]. Journal of International Oncology, 2023, 50(12): 751-757.
[11]	Liu Shaoping, Luo Hanchuan, Lin Shuhan, Luo Jiahui. Current status and research progress of interventional and systemic therapy for advanced hepatocellular carcinoma [J]. Journal of International Oncology, 2023, 50(12): 758-762.
[12]	Jiang Shan, Xu Ximing. Recent progresses of targeted therapy and immunotherapy of hepatocellular carcinoma [J]. Journal of International Oncology, 2023, 50(11): 688-695.
[13]	Jiang Shan, Xu Yangtao, Liu Xin, Chen Wenliang, Xu Ximing. Predictive value of baseline peripheral blood inflammatory biomarkers for prognosis in patients with advanced hepatocellular carcinoma treated with immunotherapy combined with targeted therapy [J]. Journal of International Oncology, 2023, 50(10): 600-607.
[14]	Sun Qi, Li Wenqian, Xie Youbang, Zhou Houfa. Research progress on the mechanism of bone marrow suppression after chemotherapy [J]. Journal of International Oncology, 2023, 50(1): 33-36.
[15]	Zhang Jingxian, Su Jianfei, Wei Xueqin, Yi Dan, Li Xiaojiang. Treatment status of non-small cell lung cancer with METexon14 skipping mutation [J]. Journal of International Oncology, 2023, 50(1): 37-41.